Endocrine, morphological, and cytological effects of a depot GnRH agonist in bovine.
The present study was conducted to assess effects of the gonadotropin-releasing hormone agonist (GnRHa) triptorelin in dairy heifers. The peptide was released from a commercial 4-week depot formulation (Decapeptyl Depot) administered at animals' estrus (day 0). First experiment (EXP I, n=5), which was aimed to explore the availability of peptide, detected a maximum of triptorelin concentration between day 2 and 5 after depot injection, and the peptide remained detectable by RIA in peripheral blood for about 3 weeks. In further experiments, the peptide release was terminated on day 9 (EXP II, n=16) or day 21 (EXP III, n=47). Treatment effects were studied on follicular development, the characteristics of cumulus-oocyte complexes (COCs) (EXP II; EXP IIIa) and secretions of LH and progesterone (EXP IIIb). Results showed that the occurrence of the pre-ovulatory LH surge was more uniform in treated heifers than that in controls. The duration of ovulation periods was similar amongst the heifers of EXP II, but more compact amongst those of EXP III each compared with the respective controls. Post-ovulatory, the number of LH pulses was significantly reduced by treatment, whereas both basal LH and progesterone concentrations were elevated on a few days. Follicular growth was reduced only by the prolonged influence of the GnRHa. There were increased proportions of both degenerated COCs and immature oocytes from small follicles (<3mm in diameter), and meiotic configuration and quality of oocytes isolated from follicles 3-5mm were changed after the prolonged, 21-day treatment. These results indicate that a continuous influence of a GnRHa over more than 1 week may increasingly impair the development of bovine follicles and oocytes. This may have some significance for the development of novel GnRH-based techniques in regulating the reproductive function in cattle.
Unit of Reproductive Biology, Research Institute for the Biology of Farm Animals, Wilhelm-Stahl-Allee 2, D-18196 Dummerstorf, Germany. falk.schneider@fbn-dummerstorf.de
F
F
Schneider
B
B
Heleil
H
H
Alm
H
H
Torner
F
F
Becker
T
T
Viergutz
G
G
Nürnberg
W
W
Kanitz
D000818:Animals; D002417:Cattle / Q000502:physiology*; D002843:Chromatin / Q000502:physiology; D003692:Delayed-Action Preparations; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D016018:Least-Squares Analysis; D007986:Luteinizing Hormone / Q000097:blood; D008186:Luteolytic Agents / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D009865:Oocytes / Q000502:physiology; D006080:Ovarian Follicle / Q000166:cytology / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000502:physiology; D011374:Progesterone / Q000097:blood; D011897:Random Allocation; D017329:Triptorelin Pamoate / Q000008:administration & dosage* / Q000097:blood / Q000493:pharmacokinetics; D014463:Ultrasonography
D002843:Chromatin; D003692:Delayed-Action Preparations; D008186:Luteolytic Agents; D017329:Triptorelin Pamoate; D007987:Gonadotropin-Releasing Hormone; D011374:Progesterone; D007986:Luteinizing Hormone